INVESTOR NOTICE: Fulgent Genetics, Inc. Investors with Substantial Losses Have the Opportunity to Conduct the Fulgent Genetics – FLGT class action lawsuit

SAN DIEGO – (COMMERCIAL LINE) –Robbins Geller Rudman & Dowd LLP announces that purchasers or purchasers of Fulgent Genetics, Inc. (NASDAQ: FLGT) securities between March 22, 2019 and August 4, 2022 inclusive (the “Class Period”) have until November 21, 2022 to apply for nomination a main actor in the Bright Genetics collective action. Subtitled Pugley v. Fulgent Genetics, Inc.No. 22-cv-06764 (CD Cal.), The Bright Genetics class action lawsuit accuses Fulgent Genetics and some of its top executives of violations of the Securities Exchange Act of 1934.

If you have suffered substantial losses and wish to serve as the main plaintiff of the Bright Genetics class action, provide your information here:

https://www.rgrdlaw.com/cases-fulgent-genetics-inc-class-action-lawsuit-flgt.html

You can also contact the lawyer JC Sanchez or Robbins Geller by calling 800 / 449-4900 or by email at jsanchez@rgrdlaw.com.

CASE ANNEXES: Fulgent Genetics provides genetic, molecular diagnostic and COVID-19 testing services to physicians and patients. Fulgent Genetics must comply with the Federal Anti-Backlash Statute, which prohibits the knowing and intentional payment of “wages” to induce or reward patient referrals or the generation of business involving any items or services payable by federal health programs, as well as the law Federal Stark, which prohibits a doctor from referring for certain designated health services, including laboratory services, which are covered by the Medicare program, to an entity with which the doctor or a close relative has a direct or indirect financial relationship .

the Bright Genetics class action lawsuit alleges that defendants did not disclose that: (i) Fulgent Genetics had conducted medically unnecessary laboratory tests, engaged in improper billing practices in relation to laboratory tests, and provided or received compensation in violation the Anti-Backlash Statute and Stark’s Law; (ii) as a result, Fulgent Genetics would have been subject to greater legal and regulatory scrutiny; (iii) the revenues of Fulgent Genetics, to the extent that they arose from the aforementioned unlawful conduct, were unsustainable; and (iv) the foregoing, once disclosed, could have caused Fulgent Genetics significant financial and / or reputational damage.

On August 4, 2022, Fulgent Genetics released its financial results for the second quarter of 2022, disclosing, among other things, that the US Securities and Exchange Commission (“SEC”) was conducting an investigation into certain Fulgent Genetics reports filed with the SEC from 2018 through the first quarter of 2020. The disclosure followed Fulgent Genetics’ receipt of a civil investigation request issued by the US Department of Justice relating to its “investigation into allegations of unnecessary laboratory tests from the Medically, improper billing for laboratory tests and compensation received or provided in violation of the Anti-Kickback Statute and the Stark Act. Upon this news, the share price of Fulgent Genetics fell more than 17%, hurting investors .

THE PROCESS OF THE PRINCIPAL COMPLAINT: The Private Securities Litigation Reform Act of 1995 allows any investor who has purchased or acquired Fulgent Genetics securities during the Class Period to apply for nomination as a principal actor. A major player is generally the movant with the greatest financial interest in the relief required by the putative class which is also typical and adequate of the putative class. A lead actor acts on behalf of all other class members by directing the Bright Genetics collective action. The lead plaintiff can select a law firm of his choice for litigation Bright Genetics collective action. An investor’s ability to participate in any potential future recovery does not depend on serving as the main plaintiff Bright Genetics collective action.

ABOUT ROBBINS GELLER: Robbins Geller is one of the world’s leading complex collective stock companies representing plaintiffs in securities fraud cases. The firm is ranked # 1 in the 2021 ISS Securities Class Action Services 50 report for recovering nearly $ 2 billion for investors last year alone, more than three times the amount recovered from any other plaintiff firm. With 200 attorneys across 9 offices, Robbins Geller is one of the largest plaintiff firms in the world and the firm’s attorneys have achieved many of the largest class action recoveries in history, including the largest class action recovery ever. realized – 7.2 billion dollars – in Regarding the Enron Corp. sec. litigation. Please visit the following page for more information:

https://www.rgrdlaw.com/services-litigation-securities-fraud.html

Attorney advertisement.

Past results do not guarantee future results.

The services can be performed by lawyers in any of our offices.

Leave a Comment

%d bloggers like this: